All In Biotech

Investigational drug · Phase 2

ALK202

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC (Advanced Non-small Cell Lung Cancer).

Phase 2

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "ALK202"

First trial start

2026

Jun 30, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ALK202", any sponsor or status.

Conditions studied

As listed on its trial records.

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "ALK202" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for NSCLC (Advanced Non-small Cell Lung Cancer)

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • SCTB41Phase 36 trials

    Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor

  • AMT-116Phase 33 trials

    Multitude Therapeutics Inc. · Advanced Solid Tumors, Advanced Non-small Cell Lung Cancer (NSCLC), NSCLC (Advanced Non-small Cell Lung Cancer)

  • JYP0322Phase 32 trials

    Guangzhou JOYO Pharma Co., Ltd · Non Small Cell Lung Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)

  • ALK201Phase 22 trials

    Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Cancer, Advanced Solid Tumors

  • ODM-212Phase 22 trials

    Orion Corporation, Orion Pharma · Solid Tumours, Mesothelioma, Pancreatic Cancer

  • TCC1727Phase 22 trials

    Beijing Tide Pharmaceutical Co., Ltd · Patients with Advanced Solid Tumors, Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)

  • BH-30643Phase 21 trial

    BlossomHill Therapeutics · NSCLC (Advanced Non-small Cell Lung Cancer)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.